140 related articles for article (PubMed ID: 37652820)
1. Real-world challenges in eligibility for MMR vaccination two years after autologous and allogeneic HSCT.
Punchhi G; Negus R; Saif H; Pritchard S; Owen O; Sehmbi A; Hamm C
Vaccine; 2023 Sep; 41(41):5936-5939. PubMed ID: 37652820
[TBL] [Abstract][Full Text] [Related]
2. Immunity and Vaccination Against Measles, Mumps, and Rubella in Adult Allogeneic Hematopoietic Stem Cell Transplant Recipients.
Kawamura K; Wada H; Nakasone H; Akahoshi Y; Kawamura S; Takeshita J; Yoshino N; Misaki Y; Yoshimura K; Gomyo A; Tamaki M; Kusuda M; Kameda K; Sato M; Tanihara A; Kimura SI; Kako S; Kanda Y
Transplant Cell Ther; 2021 May; 27(5):436.e1-436.e8. PubMed ID: 33775586
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the immune status against measles, mumps, and rubella in adult allogeneic hematopoietic stem cell transplantation recipients.
Kawamura K; Yamazaki R; Akahoshi Y; Nakano H; Ugai T; Wada H; Yamasaki R; Ishihara Y; Sakamoto K; Ashizawa M; Sato M; Terasako-Saito K; Kimura S; Kikuchi M; Nakasone H; Kanda J; Kako S; Tanihara A; Nishida J; Kanda Y
Hematology; 2015 Mar; 20(2):77-82. PubMed ID: 24992512
[TBL] [Abstract][Full Text] [Related]
4. Measles, mumps and rubella vaccine 12 months after hematopoietic stem cell transplantation.
Randi BA; Fernandes EG; Higashino HR; Lopes MH; Rocha VG; Costa SF; Sartori AMC
Rev Inst Med Trop Sao Paulo; 2023; 65():e21. PubMed ID: 36946817
[TBL] [Abstract][Full Text] [Related]
5. Successful restoration of protective immunity against measles, mumps, and rubella following MMR vaccination in adult hematopoietic cell transplant recipients.
Lin RY; Anderson AD; Morris MI; Raja M; Komanduri KV; Camargo JF
Transpl Infect Dis; 2023 Apr; 25(2):e14043. PubMed ID: 36880572
[TBL] [Abstract][Full Text] [Related]
6. Measles, mumps, and rubella revaccination in children after completion of chemotherapy and hematopoietic stem cell transplantation: a single-center prospective efficacy and safety analysis.
Wang M; Yuan Q; Deng PF; Fei Y; Zhang H; Zhou F; Chen WJ; Cao Q; Chen J; Gao YJ
World J Pediatr; 2023 Nov; 19(11):1062-1070. PubMed ID: 37087716
[TBL] [Abstract][Full Text] [Related]
7. Safety and Seropositivity after Live Attenuated Vaccine in Adult Patients Receiving Hematopoietic Stem Cell Transplantation.
Aoki T; Kamimura T; Yoshida S; Mori Y; Kadowaki M; Kohno K; Ishihara D; Urata S; Sugio T; Kamezaki K; Kato K; Ito Y; Eto T; Akashi K; Miyamoto T
Biol Blood Marrow Transplant; 2019 Aug; 25(8):1576-1585. PubMed ID: 30959161
[TBL] [Abstract][Full Text] [Related]
8. Analysis of Immunity against Measles, Mumps, Rubella, and Varicella Zoster in Adult Recipients of Allogeneic Hematopoietic Stem Cell Transplantation: A Single-Center Experience.
Yoshida S; Fujii N; Kamoi C; Kitamura W; Fujiwara H; Asada N; Nishimori H; Fujii K; Matsuoka KI; Maeda Y
Acta Med Okayama; 2022 Jun; 76(3):247-253. PubMed ID: 35790354
[TBL] [Abstract][Full Text] [Related]
9. Antibody Response against Vaccine Antigens in Children after TCRαβ-Depleted Haploidentical Stem Cell Transplantation: Is It Similar to That in Recipients with Fully Matched Donors?
Kondolot M; Yilmaz E; Erdog Sahin N; Ozcan A; Kaynar L; Unal E; Karakukcu M
Transplant Cell Ther; 2023 Feb; 29(2):128.e1-128.e9. PubMed ID: 36323399
[TBL] [Abstract][Full Text] [Related]
10. Influence of Acute and Chronic Graft-Versus-Host Disease on Persistence of Antibodies against Measles, Mumps, Rubella and Varicella in the First Year after Autologous or Allogeneic Hematopoietic Stem Cell Transplantation.
Harrison N; Burgmann H; Rabitsch W; Honsig C; Robak O
Vaccines (Basel); 2023 Mar; 11(3):. PubMed ID: 36992240
[TBL] [Abstract][Full Text] [Related]
11. An Immune Recovery-Based Revaccination Protocol for Pediatric Hematopoietic Stem Cell Transplant Recipients: Revaccination Outcomes Following Pediatric HSCT.
Haynes AS; Curtis DJ; Campbell K; Giller RH; Quinones RR; Verneris MR; Abzug MJ
Transplant Cell Ther; 2021 Apr; 27(4):317-326. PubMed ID: 33836875
[TBL] [Abstract][Full Text] [Related]
12. Serologic screening and infectious diseases consultation in renal transplant candidates for measles, mumps, rubella and varicella.
Seckin ZI; Libertin CR; Brumble LM
Rom J Intern Med; 2021 May; 59(2):159-165. PubMed ID: 33565307
[No Abstract] [Full Text] [Related]
13. Multimodal safety assessment of measles-mumps-rubella vaccination after pediatric liver transplantation.
Pittet LF; Verolet CM; McLin VA; Wildhaber BE; Rodriguez M; Cherpillod P; Kaiser L; Siegrist CA; Posfay-Barbe KM
Am J Transplant; 2019 Mar; 19(3):844-854. PubMed ID: 30171797
[TBL] [Abstract][Full Text] [Related]
14. Vaccines for measles, mumps, rubella, and varicella in children.
Di Pietrantonj C; Rivetti A; Marchione P; Debalini MG; Demicheli V
Cochrane Database Syst Rev; 2020 Apr; 4(4):CD004407. PubMed ID: 32309885
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of early vaccination with live attenuated measles vaccine for hematopoietic stem cell transplant recipients and solid organ transplant recipients.
Groeneweg L; Loeffen YGT; Versluys AB; Wolfs TFW
Vaccine; 2021 Jun; 39(25):3338-3345. PubMed ID: 33992440
[TBL] [Abstract][Full Text] [Related]
16. Response to measles, mumps and rubella vaccine in paediatric bone marrow transplant recipients.
King SM; Saunders EF; Petric M; Gold R
Bone Marrow Transplant; 1996 Apr; 17(4):633-6. PubMed ID: 8722367
[TBL] [Abstract][Full Text] [Related]
17. Revaccination with measles-mumps-rubella vaccine and hospitalization for infection in Denmark and Sweden - An interrupted time-series analysis.
Sørup S; Englund H; Laake I; Nieminen H; Gehrt L; Feiring B; Trogstad L; Roth A; Benn CS
Vaccine; 2022 Mar; 40(11):1583-1593. PubMed ID: 33518465
[TBL] [Abstract][Full Text] [Related]
18. [Antibody persistence following on different vaccination strategies of domestic measles, mumps and rubella combined attenuated live vaccine: a 3-year follow-up study].
He HQ; Li Q; Yan R; Zhou Y; Tang XW; Deng X; Xie SY; Chen ZP
Zhonghua Yu Fang Yi Xue Za Zhi; 2017 Apr; 51(4):336-340. PubMed ID: 28395468
[No Abstract] [Full Text] [Related]
19. Long-Term Follow-Up of Antibody Titers Against Measles, Mumps, and Rubella in Recipients of Allogenic Hematopoietic Cell Transplantation.
Bögeholz J; Russkamp NF; Wilk CM; Gourri E; Haralambieva E; Schanz U; Mueller NJ; Manz MG; Müller AMS
Biol Blood Marrow Transplant; 2020 Mar; 26(3):581-592. PubMed ID: 31682977
[TBL] [Abstract][Full Text] [Related]
20. Safety of Live-Attenuated Measles, Mumps, and Rubella Vaccine Administered Within 2 Years of Hematopoietic Cell Transplant.
Desjardins M; Mitre X; Sherman AC; Walsh SR; Cheng MP; Kanjilal S; Ho VT; Baden LR; Issa NC
Open Forum Infect Dis; 2021 Dec; 8(12):ofab504. PubMed ID: 34909436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
